Lessons from repurposing HIV drugs: A prospective novel strategy for drug design

Future Virology

Volumn 6, Issue 9, 2011, Pages 1021-1023

  Batman, Gavin ^a   Hampson, Lynne ^a   Hampson, Ian N ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

antitumor; HIV; HPV; off target effect; protease inhibitor

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BORTEZOMIB; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; INDINAVIR; LOPINAVIR; PROTEASOME; PROTEIN E6; RIBONUCLEASE L; UBIQUITIN;

AVIAN INFLUENZA VIRUS; DRUG DESIGN; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; KAPOSI SARCOMA; KERATINOCYTE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SARS CORONAVIRUS;

HUMAN PAPILLOMAVIRUS;

EID: 80053018174     PISSN: 17460794     EISSN: 17460808     Source Type: Journal    
DOI: 10.2217/fvl.11.75     Document Type: Review

References (21)

1. Banks L, Pim D, Thomas M. Viruses and the 26S proteasome: hacking into destruction. Trends Biochem. Sci. 28(8), 452-459 (2003) (Pubitemid 36976748)
2. Gao G, Luo H. The ubiquitin-proteasome pathway in viral infections. Can. J. Physiol. Pharmacol. 84(1), 5-14 (2006) (Pubitemid 44011945)
3. Shackelford J, Pagano JS. Targeting of host-cell ubiquitin pathways by viruses. Essays Biochem. 41, 139-156 (2005) (Pubitemid 41500976)
4. Edelmann MJ, Kessler BM. Ubiquitin and ubiquitin-like specific proteases targeted by infectious pathogens: emerging patterns and molecular principles. Biochim. Biophys. Acta 1782(12), 809-816 (2008)
5. Votteler J, Schubert U. Ubiquitin ligases as therapeutic targets in HIV-1 infection. Expert Opin. Ther. Targets 12(2), 131-143 (2008) (Pubitemid 351284957)
6. Klinger PP, Schubert U. The ubiquitin-proteasome system in HIV replication: potential targets for antiretroviral therapy. Expert Rev. Anti Infect. Ther. 3(1), 61-79 (2005) (Pubitemid 40277839)
7. Piccinini M, Rinaudo MT, Chiapello N, et al. The human 26S proteasome is a target of antiretroviral agents. AIDS 16(5), 693-700 (2002) (Pubitemid 34274459)
8. Yamamoto N, Yang R, Yoshinaka Y, et al. HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus. Biochem. Biophys. Res. Commun. 318(3), 719-725 (2004) (Pubitemid 38624214)
9. Savarino A. Expanding the frontiers of existing antiviral drugs: possible effects of HIV-1 protease inhibitors against SARS and avian influenza. J. Clin. Virol. 34(3), 170-178 (2005) (Pubitemid 41427312)
10. Bruning A, Gingelmaier A, Friese K, Mylonas I. New prospects for nelfinavir in non-HIV-related diseases. Curr. Mol. Pharmacol. 3(2), 91-97 (2010)
11. Piccinini M, Mostert M, Rinaudo MT. Proteasomes as drug targets. Curr. Drug Targets 4(8), 657-671 (2003) (Pubitemid 37236381)
12. Piccinini M, Rinaudo MT, Anselmino A, et al. The HIV protease inhibitors nelfinavir and saquinavir, but not a variety of HIV reverse transcriptase inhibitors, adversely affect human proteasome function. Antivir. Ther. 10(2), 215-223 (2005) (Pubitemid 41151027)
13. Hampson L, Kitchener HC, Hampson IN. Specific HIV protease inhibitors inhibit the ability of HPV16 E6 to degrade p53 and selectively kill E6-dependent cervical carcinoma cells in vitro. Antivir. Ther. 11(6), 813-825 (2006) (Pubitemid 44497177)
14. Batman G, OLiver AW, Zehbe I, Richard C, Hampson L, Hampson I. Lopinavir up-regulates expression of the antiviral protein ribonuclease L in human papilloma virsi postice cervical carcinoma cells. Antivir. Ther. 16(4), 515-525 (2011)
15. Zehbe I, Richard C, Lee KF, Campbell M, Hampson L, Hampson IN. Lopinavir shows greater specificity than zinc finger ejecting compounds as a potential treatment for human papillomavirus-related lesions. Antiviral. Res. 91(2), 161-166 (2011)
16. Kwara A, Delong A, Rezk N, et al. Antiretroviral drug concentrations and HIV RNA in the genital tract of HIV-infected women receiving long-term highly active antiretroviral therapy. Clin. Infect. Dis. 46(5), 719-725 (2008) (Pubitemid 351321556)
17. Schwartz AL, Ciechanover A. The ubiquitin-proteasome pathway and pathogenesis of human diseases. Ann. Rev. Med. 50, 57-74 (1999) (Pubitemid 29117052)
18. Adams J, Kauffman M. Development of the proteasome inhibitor Velcade (bortezomib). Cancer Invest. 22(2), 304-311 (2004) (Pubitemid 38725184)
19. Monini P, Sgadari C, Toschi E, Barillari G, Ensoli B. Antitumour effects of antiretroviral therapy. Nat. Rev. Cancer 4(11), 861-875 (2004) (Pubitemid 39472953)
20. Chow WA, Jiang C, Guan M. Anti-HIV drugs for cancer therapeutics: back to the future? Lancet Oncol. 10(1), 61-71 (2009)
21. Bernstein WB, Dennis PA. Repositioning HIV protease inhibitors as cancer therapeutics. Curr. Opin. HIV AIDS 3(6), 666-675 (2008)